Rocket Pharmaceuticals, Inc.
RCKT
$4.87
$0.142.96%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -42.05% | -32.31% | -8.58% | 28.44% | 36.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.77% | -24.49% | -8.19% | -4.43% | 4.01% |
| Operating Income | 29.77% | 24.49% | 8.19% | 4.43% | -4.01% |
| Income Before Tax | 29.49% | 24.56% | 1.04% | 1.16% | -1.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 29.49% | 24.56% | 1.04% | 1.16% | -1.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.49% | 24.56% | 1.04% | 1.16% | -1.12% |
| EBIT | 29.77% | 24.49% | 8.19% | 4.43% | -4.01% |
| EBITDA | 30.69% | 26.64% | 8.75% | 5.72% | -3.41% |
| EPS Basic | 38.48% | 36.34% | 16.44% | 16.01% | 3.24% |
| Normalized Basic EPS | 37.88% | 35.77% | 20.53% | 16.72% | 1.72% |
| EPS Diluted | 38.48% | 36.34% | 16.44% | 16.01% | 3.24% |
| Normalized Diluted EPS | 37.88% | 35.77% | 20.53% | 16.72% | 1.72% |
| Average Basic Shares Outstanding | 14.62% | 18.49% | 18.43% | 17.68% | 4.49% |
| Average Diluted Shares Outstanding | 14.62% | 18.49% | 18.43% | 17.68% | 4.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |